Search

Your search keyword '"Schulte-Mecklenbeck A"' showing total 6 results
Start Over Author "Schulte-Mecklenbeck A" Search Limiters Full Text Search Limiters Peer Reviewed Publication Year Range Last 50 years Journal proceedings of the national academy of sciences of the united states of america
6 results on '"Schulte-Mecklenbeck A"'

1. Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

Author

German Competence Network Multiple Sclerosis (KKNMS) and the BIONAT Network, Ostkamp, Patrick, Salmen, Anke, Pignolet, Béatrice, Görlich, Dennis, Andlauer, Till F. M., Schulte-Mecklenbeck, Andreas, Gonzalez-Escamilla, Gabriel, Bucciarelli, Florence, Gennero, Isabelle, Breuer, Johanna, Antony, Gisela, Schneider-Hohendorf, Tilman, Mykicki, Nadine, Bayas, Antonios, Bergh, Florian Then, Bittner, Stefan, Hartung, Hans-Peter, Friese, Manuel A., Linker, Ralf A., Luessi, Felix, Lehmann-Horn, Klaus, Mühlau, Mark, Paul, Friedemann, Stangel, Martin, Tackenberg, Björn, Tumani, Hayrettin, Warnke, Clemens, Weber, Frank, Wildemann, Brigitte, Zettl, Uwe K., Ziemann, Ulf, Müller-Myhsok, Bertram, Kümpfel, Tania, Klotz, Luisa, Meuth, Sven G., Zipp, Frauke, Hemmer, Bernhard, Hohlfeld, Reinhard, Brassat, David, Gold, Ralf, Gross, Catharina C., Lukas, Carsten, Groppa, Sergiu, Loser, Karin, Wiendl, Heinz, and Schwab, Nicholas

Published
2021

2. Immune signatures of prodromal multiple sclerosis in monozygotic twins

Author

Gerdes, Lisa Ann, Janoschka, Claudia, Eveslage, Maria, Mannig, Bianca, Wirth, Timo, Schulte-Mecklenbeck, Andreas, Lauks, Sarah, Glau, Laura, Gross, Catharina C., Tolosa, Eva, Flierl-Hecht, Andrea, Ertl-Wagner, Birgit, Barkhof, Frederik, Meuth, Sven G., Kümpfel, Tania, Wiendl, Heinz, Hohlfeld, Reinhard, and Klotz, Luisa

Published
2020

6. Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound.

Author

Janoschka, Claudia, Lindner, Maren, Koppers, Nils, Starost, Laura, Liebmann, Marie, Eschborn, Melanie, Schneider-Hohendorf, Tilman, Windener, Farina, Schafflick, David, Fleck, Ann-Katrin, Koch, Kathrin, Deffner, Marie, Schwarze, Anna-Sophie, Schulte-Mecklenbeck, Andreas, Metz, Imke, Meuth, Sven G., Gross, Catharina C., Hörste, Gerd Meyer zu, Schwab, Nicholas, and Kuhlmann, Tanja

Subjects
T helper cells, MULTIPLE sclerosis, NATALIZUMAB, CEREBROSPINAL fluid, PATIENTS' attitudes
Abstract

After natalizumab (NAT) cessation, some multiple sclerosis (MS) patients experience a severe disease rebound. The rebound pathophysiology is still unclear; however, it has been linked to interleukin-17-producing T-helper (Th17) cells. We demonstrate that during NAT treatment, MCAM+CCR6+Th17 cells gradually acquire a pathogenic profile, including proinflammatory cytokine production, pathogenic transcriptional signatures, brain endothelial barrier impairment, and oligodendrocyte damage via induction of apoptotic pathways. This is accompanied by an increase in Th17 cell frequencies in the cerebrospinal fluid of NAT-treated patients. Notably, Th17 cells derived from NAT-treated patients, who later developed a disease rebound upon treatment cessation, displayed a distinct transcriptional pathogenicity profile associated with altered migratory properties. Accordingly, increased brain infiltration of patient Th17 cells was illustrated in a humanized mouse model and brain histology from a rebound patient. Therefore, peripheral blood-accumulated MCAM+CCR6+Th17 cells might be involved in rebound pathophysiology, and monitoring of changes in Th17 cell pathogenicity in patients before/during NAT treatment cessation might enable rebound risk assessment in the future. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results